Home About MEB Organisation

print this page

policy and special-interest areas

In the Strategic Business Plan for 2009-2013 we identify and discuss five strategic objectives. Our objectives for the next five years are:

  • Clear all assessment backlogs by 2011
  • Continue to develop a scientifically robust, consistent and transparent assessment system
  • Assist and invest in efforts to strengthen the medicinal product regulatory chain, both at national and European level
  • Strengthen scientific underpinning
  • Knowledge must be translated and disseminated.

In 2005, the MEB published a special-interest policy paper. This paper adresses both basic disciplines as special-interest (clinical) areas.

These clinical areas are:

  • Psychiatry, dementia, epilepsy and cerebrovascular disorders
  • Vaccines
  • Female hormones and other products that influence the function of the urogenital system
  • Cardiovascular disorders 1 and treatments for associated metabolic risk factors (diabetes and obesity, including lipid-lowering medicines)
  • Oncology including haematological oncology

Back